Quantcast
Search Daily Dose & Film Annex
Loading

BIO SmartBrief

Daily Dose Newsletter

Monday
Apr232012

Biotime ($BTX) demonstrates method for the manufacture of cartilage producing cells from human embryonic stem cells 

BioTime (NYSE: BTX) and its wholly owned subsidiary OrthoCyte Corporation reported today a means of manufacturing cartilage from human embryonic stem cells that is suited for industrial scale-up of a product for the treatment of osteoarthritis.

  • The paper, published online in the peer-reviewed journal Regenerative Medicine, characterizes a progenitor cell line produced from human embryonic stem cells using proprietary ACTCellerate technology.
  • The study reports that the cells are capable of regenerating cartilage with long sought-after identification markers.
  • The study also shows that the cells can be directly expanded on a scale needed for industrial manufacture, which will be necessary in order to make transplantable cells available in commercial quantities.

PrintView Printer Friendly Version

EmailEmail Article to Friend

References (1)

References allow you to track sources for this article, as well as articles that were written in response to this article.
  • Response
    Excellent Web page, Stick to the wonderful work. Appreciate it.

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
Post:
 
Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>
« Northwest Biotherapeutics ($NWBO) completes significant milestones in DCVax-L program for brain cancer in Germany | Main | Achillion ($ACHN): Mixed Reaction from Analysts, UBS Downgrades »